← Leaderboards
Jenny C-N Chang
Baylor College Of Medicine
$6,753,372
Attributed
$9,075,666
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,538,103 · 9
By mechanism
R01$5,500,715 · 3
U54$5,462,437 · 1
U01$1,622,400 · 1
P50$1,002,857 · 1
R21$449,250 · 1
R56$299,992 · 1
Top collaborators
- Michael T Lewis5 shared
- Funda Meric-Bernstam3 shared
- Haifa Shen3 shared
- Stephen Tc Wong3 shared
- Stanley Lipkowitz2 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Susan M Blaney$10,519,074
- Mothaffar Fahed Rimawi$376,273
- Andrew Yang$152,900
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseMalignant NeoplasmsResistanceTumorClinical TrialsSignal PathwayCellsChemotherapyTherapy ResistantPathway InteractionsMalignant Breast NeoplasmBiopsyTumor GrowthNeoadjuvant TherapyPropertyInvestigationCancer TherapyCancer Stem CellSamplingMolecularBasePre-ClinicalCharacteristicsSmall Molecule
Grant awards (32)
Dual targeting of PI3K and NOS pathways in Metaplastic BreastCancer (MBC)$654,245
R01 · FY2025 · CA · contact PI
Dual targeting of PI3K and NOS pathways in Metaplastic BreastCancer (MBC)$611,983
R01 · FY2024 · CA · contact PI
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)$580,861
U01 · FY2024 · CA · contact PI
Dual targeting of PI3K and NOS pathways in Metaplastic BreastCancer (MBC)$644,191
R01 · FY2023 · CA · contact PI
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)$592,634
U01 · FY2023 · CA · contact PI
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)$448,905
U01 · FY2022 · CA · contact PI
Center for Immunotherapeutic Transport Oncophysics$1,797,348
U54 · FY2020 · CA
Targeting the Inflammasome As a Treatment Strategy for COVID-19 infected cancer patients$161,500
U54 · FY2020 · CA · contact PI
Center for Immunotherapeutic Transport Oncophysics$1,638,268
U54 · FY2019 · CA
Center for Immunotherapeutic Transport Oncophysics$1,865,321
U54 · FY2018 · CA
Biomimetic nanovesicles to overcome multiple physiological barriers for primary and metastatic triple negative breast cancer therapy$299,992
R56 · FY2017 · CA · contact PI
Targeting Notch, PI3K-AKT and Other Novel Pathways in Breast Cancer Stem Cells$433,884
R01 · FY2012 · CA · contact PI
Treatment Resistance Pathways & Targeting Residula Cancers$224,444
P50 · FY2012 · CA · contact PI
Targeting Notch, PI3K-AKT and other novel pathways in breast cancer stem cells$446,311
R01 · FY2011 · CA · contact PI
Treatment Resistance Pathways & Targeting Residula Cancers$227,561
P50 · FY2011 · CA · contact PI
Targeting Notch, PI3K-AKT and other novel pathways in breast cancer stem cells$473,769
R01 · FY2010 · CA · contact PI
Treatment Resistance Pathways & Targeting Residula Cancers$239,437
P50 · FY2010 · CA · contact PI
Targeting Notch, PI3K-AKT and other novel pathways in breast cancer stem cells$478,509
R01 · FY2009 · CA · contact PI
Breast cancer response markers to a dual HER1/2 blocker$252,236
R01 · FY2009 · CA · contact PI
Treatment Resistance Pathways & Targeting Residula Cancers$156,198
P50 · FY2009 · CA · contact PI
NSABP Participating Sites$67,765
U10 · FY2009 · CA · contact PI
Targeting Notch, PI3K-AKT and other novel pathways in breast cancer stem cells$475,325
R01 · FY2008 · CA · contact PI
Breast cancer response markers to a dual HER1/2 blocker$252,236
R01 · FY2008 · CA · contact PI
Treatment Resistance Pathways & Targeting Residula Cancers$155,217
P50 · FY2008 · CA · contact PI
NSABP Participating Sites$66,231
U10 · FY2008 · CA · contact PI
Breast cancer response markers to a dual HER1/2 blocker$252,236
R01 · FY2007 · CA · contact PI
NSABP Participating Sites$66,456
U10 · FY2007 · CA · contact PI
Breast cancer response markers to a dual HER1/2 blocker$259,769
R01 · FY2006 · CA · contact PI
Breast cancer response markers to a dual HER1/2 blocker$266,021
R01 · FY2005 · CA
MECHANISM OF ACTION OF HERCEPTIN R IN BREAST CANCER$150,500
R21 · FY2002 · CA
MECHANISM OF ACTION OF HERCEPTIN R IN BREAST CANCER$149,500
R21 · FY2001 · CA
MECHANISM OF ACTION OF HERCEPTIN R IN BREAST CANCER$149,250
R21 · FY2000 · CA